Market closed

Collegium Pharmaceutical/$COLL

14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX

About Collegium Pharmaceutical

Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.

Ticker

$COLL
Sector
Health Care
Trading on
NASDAQ

Industry

Pharmaceuticals
Headquarters
Stoughton, United States

Employees

197
Website
www.collegiumpharma.com

COLL Metrics

BasicAdvanced
$1.1B
15.62
$2.16
0.81
-

$1.1B

0.81

$40.95

$28.39

492K

0.966

0.758

395.833

423.942

3.08%

10.35%

42.89%

15.625

1.823

4.65

-1.27

5.676

9.62%

757.11%

22.53%

-7.03%

What the Analysts think about COLL

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Collegium Pharmaceutical stock.

COLL Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

COLL Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-

COLL News

AllArticlesVideos
Collegium Provides 2025 Financial Guidance and Business Update

Collegium Provides 2025 Financial Guidance and Business Update

GlobeNewsWire·7 days ago
Collegium Pharmaceutical: Strong Growth With Pain Management And ADHD Expansion

Collegium Pharmaceutical: Strong Growth With Pain Management And ADHD Expansion

Seeking Alpha·2 months ago
Knight Therapeutics Announces Health Canada Approval for JORNAY PM™ to Treat Attention-Deficit Hyperactivity Disorder (ADHD)

Knight Therapeutics Announces Health Canada Approval for JORNAY PM™ to Treat Attention-Deficit Hyperactivity Disorder (ADHD)

GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $COLL

$

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Collegium Pharmaceutical stock?

Collegium Pharmaceutical (COLL) has a market cap of $1.1B as of January 15, 2025.

What is the P/E ratio for Collegium Pharmaceutical stock?

The price to earnings (P/E) ratio for Collegium Pharmaceutical (COLL) stock is 15.62 as of January 15, 2025.

Does Collegium Pharmaceutical stock pay dividends?

No, Collegium Pharmaceutical (COLL) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next Collegium Pharmaceutical dividend payment date?

Collegium Pharmaceutical (COLL) stock does not pay dividends to its shareholders.

What is the beta indicator for Collegium Pharmaceutical?

Collegium Pharmaceutical (COLL) has a beta rating of 0.81. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.